CANY
AMED

Caxton Associates (New York)’s Amedisys AMED Stock Holding History

Caxton Associates (New York)’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-9,237
Closed -$679K – 484
2023
Q1 		$679K Sell
9,237
-5,063
-35% -$438K 0.1% 210
2022
Q4 		$1.19M Buy
14,300
+1,914
+15% +$173K 0.08% 89
2022
Q3 		$1.2M Buy
12,386
+2,424
+24% +$289K 0.16% 80
2022
Q2 		$1.05M Buy
+9,962
New +$1.27M 0.1% 116
2022
Q1 		– Sell
-4,557
Closed -$738K – 504
2021
Q4 		$738K Sell
4,557
-4,249
-48% -$683K 0.08% 178
2021
Q3 		$1.31M Buy
8,806
+7,743
+728% +$1.61M 0.15% 72
2021
Q2 		$260K Buy
+1,063
New +$279K 0.03% 351
2020
Q4 		– Sell
-6,551
Closed -$1.55M – 146
2020
Q3 		$1.55M Buy
6,551
+4,050
+162% +$921K 0.16% 40
2020
Q2 		$497K Buy
2,501
+313
+14% +$58.4K 0.04% 141
2020
Q1 		$402K Buy
+2,188
New +$389K 0.07% 198
2019
Q2 		– Sell
-3,143
Closed -$387K – 393
2019
Q1 		$387K Sell
3,143
-731
-19% -$91.7K 0.06% 188
2018
Q4 		$454K Buy
3,874
+1,945
+101% +$229K 0.07% 126
2018
Q3 		$241K Buy
+1,929
New +$213K 0.02% 353

Other funds holding AMED

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Caxton Associates (New York)'s AMED Position: Q2 2023 in Review

Caxton Associates (New York) sold out of Amedisys (AMED) in Q2 2023, closing a stake of 9,237 shares — an estimated $679K sold.

Caxton Associates (New York) first reported a position in AMED in Q3 2018 and held it in 13 quarters. The position peaked at $1.55M in Q3 2020. 301 funds tracked by Wall St. Rank hold AMED as of Q2 2023.

  • Caxton Associates (New York) reported no remaining Amedisys position as of Q2 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 9,237 Amedisys shares in Q2 2023, an estimated $679K.
  • Caxton Associates (New York) first reported a position in Amedisys in Q3 2018 and held it in 13 quarters.
  • Caxton Associates (New York)'s Amedisys position peaked at $1.55M in Q3 2020.
  • 301 funds tracked by Wall St. Rank held Amedisys as of Q2 2023.

Based on Caxton Associates (New York)'s 13F filing for Q2 2023, filed 15 Aug 2023.